ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 925

Incidence of Dementia and Association with Cardiovascular Disease and Risk Factors in Rheumatoid Arthritis – Analysis of a National Claims Database

Sebastian E. Sattui1, Mangala Rajan 2, Sarah Lieber 1, Geyanne Lui 3, Jeffrey Curtis 4, Lisa Mandl 5 and Iris Navarro-Millan 2, 1Hospital for Special Surgery, New York, 2Weill Cornell Medicine, New York, 3Weill-Cornell Medicine, New York, NY, 4University of Alabama at Birmingham, Birmingham, AL, 5Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, New York, NY

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: cardiovascular disease and outcomes, Dementia, Rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: 3S108: RA – Diagnosis, Manifestations, & Outcomes II: Cardiovascular Comorbidities (921–926)

Session Type: ACR Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Inflammation has been thought to be a risk factor for cognitive impairment and dementia. RA, an autoimmune inflammatory disorder is associated with a high risk of cardiovascular disease (CVD) as a result of underlying inflammation, However, it is unknown if RA patients at risk of CVD are similarly at higher risk of developing dementia. The objective of this study was to describe the incidence of dementia among patients with RA older than 40 years, and to compare the risk of incident dementia between those with known CVD and those without CVD, with and without traditional CVD risk factors.

Methods: We conducted a longitudinal analysis, using Centers for Medicare and Medicaid claims (CMS) data from 2006-2014. To be included, patients had to be continuously enrolled throughout 2006 (12 months calendar year of fee for service), > 40 years old, eligible for Medicare parts A, B and D, and without a diagnosis of dementia in 2006. RA was defined as: two RA diagnoses (ICD-9-CM 714.xx) by a rheumatologist > 7 and < 365 days apart and or at least one diagnosis of RA and least 1 prescription for a DMARD. Incident dementia was defined as: 2 outpatient claims for dementia (ICD-9-CM codes for 290.xx, 294.1x, or 331.xx) at least 40 days apart in 2007 or later. Prevalent CVD was defined by ICD-9-CM codes for myocardial infarction, heart failure, stroke, or CVD procedures (coronary artery bypass grafting, percutaneous coronary intervention, or carotid endarterectomy) in 2006. CVD risk factors were defined by ICD-9-CM codes for diabetes, hyperlipidemia, hypertension, and obesity in 2006. Age-adjusted incidence rates (IR) were estimated using Poisson models. Age- and sex-adjusted Cox proportional hazard models (HR) were used to compare risk of incident dementia in 3 groups of RA patients; 1) with prevalent CVD 2) without CVD but with CVD risk factors, and 3) no prevalent CVD events nor CVD risk factors.

Results: There were 79,957 RA patients in the study sample; 80.8% were female, and 79.6% were white (Table 1). The prevalence of dementia was 2.36% (n = 1,887). After removing RA patients with prevalent dementia in 2006, 75,634 remained. Between 2007-2014, there were 9,835 (13%) cases of incident dementia (Table 1). The age-adjusted IR of dementia was 25.6 (95% CI 24.3 – 26.9) per 1000 person-years for those with prevalent CVD, 17.5 (95% CI 17.1 – 18.1) per 1000 person-years for those with CVD risk factors, and 15.2 (95% CI 14.59-16.00) in patients with neither (Table 2). The age- and sex-adjusted HR for incident dementia was 2.1 (95% CI 1.9 – 2.2) in those with prevalent CVD and 1.2 (95% CI 1.1 – 1.2) in those without prevalent CVD with presence of any CVD risk factor compared to those without CVD and or CVD risk factors.

Conclusion: The incidence of dementia in patients with RA was as high or higher than previous reports from the general population. The presence of CVD in patients with RA increases the risk for incident dementia 2-fold when compared to patients with RA without CVD or CVD risk factors. Our study suggests that in patients with RA, increasing risk for CVD may also be associated with an increased risk for dementia. Further studies comparing patients with and without RA are needed to clarify this association.


Table 1

CVD = cardiovascular disease; Prevalent CVD as defined by ICD-9-CM codes for myocardial infarction, heart failure, stroke, or CVD procedures -coronary artery bypass grafting, percutaneous coronary intervention, or carotid endarterectomy-; CVD risk factors included diabetes, hyperlipidemia, hypertension, and obesity in 2006 defined by ICD-9-CM codes.


Table 2

CVD = cardiovascular disease; Prevalent CVD as defined by ICD-9-CM codes for myocardial infarction, heart failure, stroke, or CVD procedures -coronary artery bypass grafting, percutaneous coronary intervention, or carotid endarterectomy-; CVD risk factors included diabetes, hyperlipidemia, hypertension, and obesity in 2006 defined by ICD-9-CM codes.


Disclosure: S. Sattui, None; M. Rajan, None; S. Lieber, None; G. Lui, None; J. Curtis, AbbVie, 2, 5, Abbvie, 2, 5, AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Lilly, Janssen, Myriad, Pfizer, Regeneron, Roche, and UCB, 2, 5, Amgen, 2, 5, Amgen Inc., 2, 5, BMS, 2, 5, Bristol-Myers Squibb, 2, 5, Corrona, 2, 5, Crescendo, 2, 5, Eli Lilly, 2, 5, Eli Lilly and Company, 2, 5, Genentech, 2, 5, Janseen, 5, Janssen, 2, 5, Janssen Research & Development, LLC, 2, Lilly, 2, 5, Myriad, 2, 5, Patient Centered Outcomes Research Insitute (PCORI), 2, Pfizer, 2, 5, Radius Health, Inc., 9, Regeneron, 2, 5, Roche, 2, 3, 5, Roche/Genentech, 5, UCB, 2, 5; L. Mandl, Annals of Internal Medicine, 3, Annals of Internal Medicine- Associate Editor, 3, UpToDate, 7, Wolters Kluwer - Author at UptoDate, 7, Wolters Kluwer - Author at UpToDate, 7, Wolters Kluwer- Author at UpToDate, 7; I. Navarro-Millan, None.

To cite this abstract in AMA style:

Sattui S, Rajan M, Lieber S, Lui G, Curtis J, Mandl L, Navarro-Millan I. Incidence of Dementia and Association with Cardiovascular Disease and Risk Factors in Rheumatoid Arthritis – Analysis of a National Claims Database [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/incidence-of-dementia-and-association-with-cardiovascular-disease-and-risk-factors-in-rheumatoid-arthritis-analysis-of-a-national-claims-database/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/incidence-of-dementia-and-association-with-cardiovascular-disease-and-risk-factors-in-rheumatoid-arthritis-analysis-of-a-national-claims-database/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology